Real-World Clinical Impact of Tafamidis on Transthyretin Amyloid Cardiomyopathy ― A Decade of Experience From a Community-Based Hospital (2015–2024) ―
In this real-world cohort, tafamidis treatment was significantly associated with better survival in ATTR-CM patients, particularly when initiated in the early stage. Therefore, early detection and timely initiation of treatment are critical for optimizing clinical outcomes in this increasingly recognized condition.
Authors
- Nobuhiro Suematsu
- Daisuke Nagatomo (ORCID: https://orcid.org/0000-0002-0186-1502)
- Toru Kubota
- Akihito Ishikita (ORCID: https://orcid.org/0000-0002-9102-6649)
- Masatsugu Nozoe (ORCID: https://orcid.org/0000-0002-8450-573X)
- Seiya Kato (ORCID: https://orcid.org/0000-0003-1390-7229)
Institutions
- Saiseikai Fukuoka General Hospital (JP)
Publication Details
- Journal
- Circulation Reports
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1253/circrep.cr-25-0031
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00